newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - STOKE THERAPEUTICS INC

  • Explicit Guidance:

    • No financial guidance (revenue, earnings, capex, etc.) or specific milestone timing (e.g., "Q3 202X") was provided for future periods. The transcript confirms the primary efficacy endpoint (seizure reduction) is scheduled for Week 28 of the ongoing Phase III study, with the company noting they are currently "four weeks away" from this endpoint for the 130 patients who have completed Week 24 as of the Q3 update.
  • Business-Segment Outlook:

    • Lead Program (Zirivinersan): The company anticipates the Phase III study will successfully hit its primary endpoint (seizure reduction) and secondary endpoints (cognition/behavior). Management asserts the study is "well-powered" to achieve a P-value <0.05 for seizure reduction (targeting a ~46% treatment difference) and the secondary MC4 score (targeting >1.8 improvement).
    • Next Program (ADOA): Following success in Dravet syndrome, the company anticipates applying the same protein-upregulation mechanism to Autosomal Dominant Optic Atrophy (ADOA) with the expectation of clinical benefits and potential vision restoration.
    • Pipeline Expansion: The company plans to pursue earlier-stage efforts focused on haploinsufficient diseases, primarily within the neuroscience and neurology sectors.
  • Market and Competitive Outlook:

    • Pricing Strategy: Stoke expects to price Zirivinersan competitively with established gene-targeted rare disease assets, specifically citing Spinraza, Exon Skippers (Sarepta), and Beqvez (Rett syndrome) as pricing analogs.
    • Addressable Market: The company estimates an immediate US addressable population of approximately 6,000 diagnosed patients (including those 25 and younger and adults transitioning from pediatric care), with a total estimated population of 16,000. The market is expected to grow via an influx of 40–50 new diagnoses monthly (500–600 annually), with 30% of new cases identified in adults.
    • Reimbursement: Management anticipates payers will prioritize long-term Open-Label Extension (OLE) data (4+ years) over short-term Phase III endpoints when evaluating coverage, due to the chronic nature of the disease.
  • Macro / Industry Outlook:

    • Regulatory Alignment: The company expects continued collaboration with the FDA to refine endpoint definitions (e.g., shifting from hierarchical to a basket "MC4" score for cognition) to better reflect the drug's holistic benefits and enhance study powering.
    • Disease Understanding: Management notes a structural shift in the Dravet syndrome landscape, with earlier diagnosis ages and a growing cohort of adults being correctly diagnosed, potentially expanding the treatment window.
  • Strategic Initiatives:

    • Phase III Execution: The company is currently recruiting 162 patients for the pivotal study. Progress is reported as robust, with zero dropouts and 130 patients completing the required doses for the primary analysis (Week 24) two weeks prior to the call.
    • Data Validation: Leverage of 4-year OLE data (covering ~75–80 patients) to demonstrate sustained seizure reduction (80–85%) and cognitive improvements (8–11 Vineland points) to support regulatory filing and market access.
  • Risks and Headwinds to Outlook:

    • Regulatory Requirement: Despite strong preclinical and OLE data, the drug must achieve statistical significance on the primary endpoint in the Phase III trial for approval; a failure to hit the P-value threshold remains the primary binary risk.
    • Endpoint Complexity: While the FDA agreed to the MC4 scoring for secondary endpoints to improve powering, the study still relies on the primary seizure reduction endpoint which requires specific statistical separation from placebo.
    • Market Adoption: Pricing power is contingent on payer acceptance of the "cognitive benefit" narrative, which may face hurdles if not explicitly captured in the final drug label compared to the totality of evidence.
  • Management Tone on the Future:

    • Confidence Level: High. The CEO explicitly states, "I believe we will reach our secondary endpoints" and describes the study progress as "very good."
    • Rationale: Confidence is derived from the high probability of hitting the primary seizure endpoint (80–85% reduction vs. 46% target) and the robustness of long-term safety/efficacy data (5 years of patient exposure, zero dropouts).
    • Perspective: Management views the FDA as a "friend," emphasizing that recent regulatory interactions have improved the understanding of the disease and drug mechanism, leading to a more favorable statistical approach (MC4) for the study.
  • Miscellaneous:

    • Mechanism of Action: The drug targets the root cause (Nav1.1 protein deficiency) rather than just symptoms, aiming to restore neurotypical development that typically "flatlines" after age 2 in Dravet syndrome patients.
Company
STOKE THERAPEUTICS INC
Keywords
STOKE THERAPEUTICS INC